The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human (FiH) phase I study of GFS202A, a GDF15/IL-6 bispecific antibody, in advanced cancer patients (pts) with pre-cachexia or cachexia.
 
Hongyun Zhao
No Relationships to Disclose
 
Da Li
No Relationships to Disclose
 
Yuxiang Ma
No Relationships to Disclose
 
Hong Zong
No Relationships to Disclose
 
Yusheng Wang
No Relationships to Disclose
 
Xiangcai Wang
No Relationships to Disclose
 
Haiyu Yang
No Relationships to Disclose
 
Zhen Li
No Relationships to Disclose
 
Qian Chu
No Relationships to Disclose
 
Yue Shan
Employment - Genfleet Therapeutics
 
Lingyu Tai
Employment - Genfleet Therapeutics
 
Jiani Song
Employment - Genfleet Therapeutics
 
Yue Zhang
Employment - Genfleet Therapeutics
 
Huaqiang Zhu
Employment - Genfleet Therapeutics
 
Haige Shen
Employment - Genfleet Therapeutics
Stock and Other Ownership Interests - Genfleet Therapeutics; Laekna Therapeutics
 
Yu Wang
Employment - Genfleet Therapeutics
 
Li Zhang
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Akeso Biopharma; AstraZeneca; CHINA SHIYAO PHARMA; HenRui; Roche; Sichuan Biokin Pharmaceutical
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); QiLu Pharmaceutical (Inst); Sichuan Biokin Pharmaceutical, (Inst); Sichuan Kelun-Biotech Biopharmaceutical (Inst)